|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Stem Cell Transplantation in Children: Current Results and Controversies - #7 | ||||||||||||||||
| January 09, 2003 | ||||||||||||||||
|
A. I. duPont Hospital for Children, Hilton Head Island, South Carolina March 6-8, 2003 Thursday, March 6, 2003 SESSION I 8:45 a.m. A. Transplant-Related Issues Rainer Storb, MD: History of Pediatric Stem Cell Transplantation John Perentesis, MD: Myeloablative Preparative Therapy for Transplantation Rainer Storb, MD: Non-Myeloablative Transplantation - State-of-the-Art B. Source of Stem Cells Stella Davies, MD, PhD: Unrelated Donors and Alternative Donors Frank Smith, MD: Use of Cord Blood SESSION II 2:15 p.m. Michael Boeckh, MD: Prevention and Management of CMV Infection and Disease Thomas J. Walsh, MD: Immune Compromised Stem Cell Patients D. Brain Tumors and Other CNS Malignancies Sharon L. Gardner, MD: Application of Stem Cell Transplant for Brain Tumors Friday, March 7, 2003 SESSION III 8:00 a.m. E. Sickle Cell Disease Mark C. Walters, MD: Sickle Cell Disease and Mini-Transplants George Buchanan, MD: The Case Against Using High Dose Therapy and Stem Cell Rescue for Patients with Sickle Cell Disease – Are There Alternatives? F. Supportive Care Jean Sanders, MD: Endocrinologic Complications of High Dose Therapy with Stem Cell Transplant Leonard A. Mattano, Jr., MD: Strategic Approaches to Osteoporosis in Transplantation Joseph P. Neglia, MD: Quality of Life Issues Saturday, March 8, 2003 SESSION IV 8:00 a.m. G. Neuroblastoma To be determined: Controversial Issues in Neuroblastoma Morris Kletzel, MD: Controversies in the Treatment of High Risk Neuroblastoma H. Chairman’s Symposium Stefan Burdach, MD: Treatment of Advanced Ewing Tumors (ET) in 2002 and Beyond: Matching Radiochemotherapy and Immunotherapy by Engineered Cellular Transplant Stephen A. Feig, MD: The Role of Stem Cell Rescue in Ewing’s Sarcoma Daniel Weisdorf, MD: Future of Transplantation 12:00 noon Adjourn – Lunch on your own |
||||||||||||||||
| Organized by: | Michael E. Trigg, MD | |||||||||||||||
| Invited Speakers: | Rainor Storb, MD: History of Pediatric Stem Cell Transplantation John Peter Perentesis, MD, F.A.A.P.: Myeloablative Preparative Therapy for Transplantation Rainor Storb, MD: Non-Myeloablative Transplantation - State-of-the-Art Stella Davies, MD PhD: Unrelated Donors and Alternative Donors Frank Smith, MD: Use of Cord Blood Michael Boeck, MD: CMV Disease and Prophylaxis Thomas J. Walsh, MD: The Immune Compromised Stem Cell Patients Sharon L. Gardner, MD: Application of stem cell transplant for central nervous system tumors Mark C. Walters, MD: Sickle Cell Disease and Mini-Transplants George Buchanan, MD: Case Against Using High Dose Therapy and Stem Cell Rescue for Patients with Sickle Cell Disease – Are There Alternatives? Jean Sanders, MD: Endocrinologic Complications of High Dose Therapy with Stem Cell Transplant Leonard A. Mattano, Jr., MD: Osteopenia in the Patient Undergoing High Dose Therapy and Stem Cell Rescue Joseph P. Neglia, MD: Quality of Life Issues C. Patrick Reynolds, MD, PhD: Controversial Issues in Neuroblastoma Morris Kletzel, MD: Controversial Issues in Neuroblastoma Stefan Burdach, MD, PhD: Treatment of High Risk, Metastatic, and Recurrent Ewing’s Stephen A. Feig, MD: Treatment of High Risk, Metastatic, and Recurrent Ewing’s Daniel Weisdorf, MD: Future of Transplantation |
|||||||||||||||
| Deadline for Abstracts: | December 31, 2003 | |||||||||||||||
| Registration: | Physicians $500 Accompanying persons [meals only] $100 Nurses and physician assistants $300 Physicians-in-training and $150 other Allied Health Professionals | |||||||||||||||
| E-mail: | jdanbois@nemours.org | |||||||||||||||
| Posted by: | Jeanne M. Danboise | |||||||||||||||
| Host: | 207.103.18.251 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||